Problems › Should We Buy a Competitor? › Healthcare Providers
Acquisitions fail on integration far more often than on price, and the integration cost is the number least likely to have been estimated. This page works through it for healthcare providers specifically — including an unedited excerpt from a real analysis of a healthcare provider.
Acquisitions fail on integration far more often than on price, and the integration cost is the number least likely to have been estimated. For healthcare providers, this shows up in a particular place. The numbers that carry the answer are cost per episode and payer mix, and the complication specific to this industry is that downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it. The general version of this problem and the one you are actually in have different first moves.
The case for buying a competitor is usually built on revenue synergies, which are the least reliable category of benefit and the slowest to arrive. Cost synergies are more predictable, and the honest ones are usually smaller than the model assumes.
The number that decides most outcomes is integration cost — systems, people, customer disruption, and the management attention diverted from the existing business for a year or more. It is routinely omitted because it is hard to estimate and does not appear on either company's accounts.
The disciplined version asks what specifically you get that you could not build or buy more cheaply another way, and what the business looks like if none of the revenue synergies materialise.
These three together are the signature. One on its own usually points somewhere else.
✓ The rationale leans on cross-selling to each other's customers
✓ Integration is described but not costed
✓ The acquisition is partly motivated by the core business having stalled
The move that usually makes it worse. Underwriting the deal on revenue synergies, which typically arrive late, smaller than modelled, or not at all.
It is for you if you run or finance a healthcare provider and the rationale leans on cross-selling to each other's customers. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on a healthcare provider. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Customer Value Architecture · sample company profile
The move. Convert existing downside-risk scale into CMS-mandated quality infrastructure that locks in 48+ month structural durability.
The leak it closes. Binary default risk on $6.8M revenue eliminated through cost-per-episode analytics
The assumption it rests on. CMS continues ACO REACH program through 2030 — the engine put the probability at 0.85.
| Investment required | $225-325K total over 36 months ($75K regulatory consultant + $150-250K analytics tooling) |
| Expected return | 69.8× on $325K investment if ACO REACH approved — derived from $22.7M NPV upside / $325K investment |
| Revenue, year 1 | $0 incremental (application phase) |
| Revenue, year 2 | $1.0M incremental (0.5 point margin lift on $196M) |
| Revenue, year 3 | $2.0M incremental (1.0 point margin lift on $196M) |
| Exit criteria | Abandon if CMS terminates ACO REACH program OR physician ownership falls below 55% OR application rejected after two submissions |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Growth Portfolio Framework, one of 29 engagements the platform runs. For healthcare providers it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.
Twice — once standalone, and once for what it is worth specifically to you. The gap between those is the most you can pay and still create value, and it is usually narrower than expected.
Cost, substantially. They are within your control and can be scheduled. Revenue synergies depend on customers behaving as modelled, which is the assumption most often wrong.
Integration consuming more management attention than anyone budgeted, so that both businesses underperform during the period the deal was supposed to be paying back.
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.